SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation - PubMed (original) (raw)
. 2002 Jul 1;62(13):3861-7.
Affiliations
- PMID: 12097301
SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation
Yuntao Xie et al. Cancer Res. 2002.
Abstract
The SYT-SSX fusion gene has been implicated in the malignant tumor cell growth of synovial sarcoma, but the underlying molecular mechanisms are still poorly understood. Here we demonstrate that SYT-SSX is critical for the protein level of cyclin D1 in synovial sarcoma cells. Antisense oligonucleotides to SYT-SSX mRNA rapidly and drastically decreased cyclin D1 and subsequently inhibited cell growth. This effect is specific for SYT-SSX, without involving the wild-type genes SYT or SSX. The decrease in cyclin D1 expression, which occurred shortly after inhibition of SYT-SSX expression, was found to be primarily dependent on an increased degradation of the cyclin D1 protein, as assessed by pulse-chase experiments using [(35)S]methionine. Furthermore, transfection of mouse fibroblasts with SYT-SSX cDNA increased the stability of cyclin D1. Because treatment with a proteasome inhibitor restored cyclin D1 expression, it seems like SYT-SSX interferes with ubiquitin-dependent degradation of cyclin D1. However, SYT-SSX-regulated cyclin D1 expression was proven to be independent of the glycogen synthetase kinase-3beta pathway. Taken together, our study provides evidence that SYT-SSX stabilizes cyclin D1 and is critical for cyclin D1 expression in synovial sarcoma cells. SYT-SSX-dependent expression of cyclin D1 may be an important mechanism in the development and progression of synovial sarcoma and also raises the possibility for targeted therapy.
Similar articles
- The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery.
Xie Y, Skytting B, Nilsson G, Grimer RJ, Mangham CD, Fisher C, Shipley J, Bjerkehagen B, Myklebost O, Larsson O. Xie Y, et al. Oncogene. 2002 Aug 22;21(37):5791-6. doi: 10.1038/sj.onc.1205700. Oncogene. 2002. PMID: 12173050 - SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.
Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. Kawai A, et al. N Engl J Med. 1998 Jan 15;338(3):153-60. doi: 10.1056/NEJM199801153380303. N Engl J Med. 1998. PMID: 9428816 - Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.
Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM, Gusterson BA, Cooper CS. Clark J, et al. Nat Genet. 1994 Aug;7(4):502-8. doi: 10.1038/ng0894-502. Nat Genet. 1994. PMID: 7951320 - Fusions of the SYT and SSX genes in synovial sarcoma.
Ladanyi M. Ladanyi M. Oncogene. 2001 Sep 10;20(40):5755-62. doi: 10.1038/sj.onc.1204601. Oncogene. 2001. PMID: 11607825 Review. - SYT-SSX fusion genes in synovial sarcoma of the thorax.
Yano M, Toyooka S, Tsukuda K, Dote H, Morimoto Y, Ohata N, Ichimura K, Aoe M, Date H, Shimizu N. Yano M, et al. Lung Cancer. 2004 Jun;44(3):391-7. doi: 10.1016/j.lungcan.2003.11.011. Lung Cancer. 2004. PMID: 15140553 Review.
Cited by
- Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.
Przybyl J, Jurkowska M, Rutkowski P, Debiec-Rychter M, Siedlecki JA. Przybyl J, et al. Sarcoma. 2012;2012:249219. doi: 10.1155/2012/249219. Epub 2012 Mar 25. Sarcoma. 2012. PMID: 22550415 Free PMC article. - Overactive IGF1/Insulin Receptors and NRASQ61R Mutation Drive Mechanisms of Resistance to Pazopanib and Define Rational Combination Strategies to Treat Synovial Sarcoma.
Lanzi C, Dal Bo L, Favini E, Tortoreto M, Beretta GL, Arrighetti N, Zaffaroni N, Cassinelli G. Lanzi C, et al. Cancers (Basel). 2019 Mar 22;11(3):408. doi: 10.3390/cancers11030408. Cancers (Basel). 2019. PMID: 30909453 Free PMC article. - Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.
Isoyama S, Tamaki N, Noguchi Y, Okamura M, Yoshimatsu Y, Kondo T, Suzuki T, Yaguchi SI, Dan S. Isoyama S, et al. Cell Death Dis. 2023 Feb 27;14(2):169. doi: 10.1038/s41419-023-05690-7. Cell Death Dis. 2023. PMID: 36849535 Free PMC article. - Molecular genetics of pediatric soft tissue tumors: clinical application.
Chang CC, Shidham VB. Chang CC, et al. J Mol Diagn. 2003 Aug;5(3):143-54. doi: 10.1016/S1525-1578(10)60466-7. J Mol Diagn. 2003. PMID: 12876204 Free PMC article. Review. - Expression levels of ARHI and Beclin1 in thyroid cancer and their relationship with clinical pathology and prognosis.
Zhu H, Qu Y. Zhu H, et al. Oncol Lett. 2020 Feb;19(2):1241-1246. doi: 10.3892/ol.2019.11223. Epub 2019 Dec 17. Oncol Lett. 2020. PMID: 31966053 Free PMC article.